Loading…
Maker of sample-preparation and molecular testing technologies for life-science research, applied testing and molecular diagnostics.
Maker of sample-preparation and molecular testing technologies for life-science research, applied testing and molecular diagnostics.
Places instruments in labs and earns mostly on the consumable kits used on them: each test run uses a kit, so the installed base of machines generates repeat purchases. Its QuantiFERON tuberculosis blood test is run as a kit by testing labs. It is Dutch-domiciled, with most sales in the US and Europe.
Moat: narrow (installed base, switching costs, IP / patents). Entrenched sample-prep technology embedded in customers' validated workflows across research and diagnostics.
Headquarters: Venlo, Netherlands · Founded: 1984 · Employees: 5,654
Size Qiagen (QGEN) is a United States Health Care company (Medical Specialties) with a market value of $10.4B, the 755th largest of 3,117 United States companies the cockpit tracks. Shares closed at $50.33 on 6 Nov 2026.
Performance Over six months the shares gained 52.3%, against +30.0% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 3.0% over the last twelve months (peer median +5.7%); the operating margin is 24.6% (peer median 13.2%).
Valuation It trades at 19.8× forward earnings against a peer median of 20.2× (11th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.4 points above its cost of capital (7.3% WACC).
Short interest Short interest is 3.5% of the free float (15 Oct 2026).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.10B | $2.09B | $1.98B | $1.97B | $2.14B |
| Revenue growth | — | +6% | +1% | -8% | — |
| Gross profit | $1.30B | $1.29B | $1.25B | $1.22B | $1.37B |
| EBITDA | $719M | $735M | $698M | $651M | $785M |
| Net income | $409M | $425M | $83.6M | $341M | $423M |
| Free cash flow | $448M | $453M | $506M | $310M | $586M |
| Capital expenditure | $214M | $207M | $171M | $163M | $149M |
| Total debt | $1.64B | $1.81B | $1.51B | $1.61B | $1.96B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Qiagen QGEN | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Danaher DHR | $162B | +35% | +6% | 21% | 25.3× | 20.5% |
| Illumina ILMN | $32.2B | +50% | +6% | 21% | 35.7× | 27.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | QGEN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.0% | +9.0% | 8th highest of 21 |
| 6-month return | +52.3% | +30.0% | 4th highest of 21 |
| Distance from 52-week high | -12.9% | -12.0% | 10th lowest of 21 |
| Revenue growth (TTM) | +3.0% | +5.7% | 7th lowest of 21 |
| Operating margin | 24.6% | 13.2% | highest of 21 |
| Forward P/E | 19.8× | 20.2× | 11th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 8.8% | 10.6% | 7th least demanding of 19 |
| Growth delivered (Del g) | +2.2% | +9.9% | 4th lowest of 19 |
| Hurdle (Req g minus delivered) | +6.5 pp | +1.3 pp | 7th most demanding of 19 |
| ROIC minus cost of capital | +2.4 pp | +2.4 pp | 11th highest of 21 |
| EV / EBITDA | 15.6× | 12.2× | 6th most expensive of 18 |
| Net debt / EBITDA | 1.2× | 0.7× | 9th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qiagen QGEN | United States | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% | +2.2% |
| Avantor AVTR | United States | $10.5B | +86% | +1% | 8% | 17.7× | 16.1% | +0.5% |
| Bio-Rad Laboratories BIO | United States | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% | +0.3% |
| Insulet PODD | United States | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% | +24.5% |
| Globus Medical GMED | United States | $9.54B | -9% | +20% | 22% | 14.1× | 5.5% | +30.1% |
| Demant A/S DEMANT.CO | Denmark | $11.6B | +62% | +10% | 18% | 25.7× | 6.8% | +9.8% |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
| Align Technology ALGN | United States | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% | +10.3% |
| Cooper Companies (The) COO | United States | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% | +11.0% |
| Olympus 7733.T | Japan | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% | +6.7% |
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% | +5.5% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 46.9× | n/a | n/a |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |